Sobi receives approval from the FDA for once-daily dosing frequency of Orfadin® for the treatment of HT-1
Swedish Orphan Biovitrum AB (publ) (Sobi™) has received approval from the U.S. Food and Drug Administration (FDA) for a reduced dosing frequency for Orfadin® (nitisinone) from twice daily to once daily in patients 5 years of age and older. The approval is based on the results of a clinical study in 16 people with hereditary tyrosinaemia type 1 (HT-1), comparing a four week once-daily and four week twice daily dosing regimen. Orfadin is approved in combination with dietary restriction of tyrosine and phenylalanine for people with HT-1, a rare genetic disorder that
Located in sunny and windy Cape Verde, Cabeolica has chosen Breeze to provide wind farm management system.The company’s main objective is the production of electricity for the national grid as an independent producer using non-polluting, renewable and naturally abundant wind energy.
With 4 wind farms on 4 islands – Santiago, São Vicente, Sal and Boa Vista – Cabeolica generates roughly 22% of the electricity consumed on the country’s main islands, avoiding, on average, the production of approximately 55,000 tons of greenhouse gases per year, in addition to contributing toward reducing
